News

TipRanks on MSN6h
Novo Nordisk’s Stock Soars Amid Strategic Moves
Novo Nordisk ( ($NVO) ) has risen by 10.44%. Read on to learn why. Novo Nordisk has seen a notable 10.44% increase in its stock price over the ...
The Print on MSN16h
India sees 20k bariatric surgeries a year. But blockbusters Mounjaro, Wegovy are shaking up obesity arena
India's anti-obesity drug market is valued at Rs 3,000-3,500 crore and is projected to grow nearly eightfold to Rs 25,000 ...
HIMS STOCK UPDATE: Hims & Hers Health, Inc. (NYSE:HIMS) Is Being Sued For Securities Fraud Contact BFA Law By August 25 Class Action Deadline
Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for ...
Myth versus fact: What we know about the risks and side effects of the new weight-loss drugs
The risks of the new weight-loss drugs can sound scary, and there’s lots of talk about side effects. What does evidence show?
Lawmakers press FDA to target knockoff weight-loss drug
Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid ...
Arizona Daily Star22h
Weight-loss drugs too costly for AZ patients on Medicaid, until obesity leads to diabetes
Editors: Story has been updated from original, with material from the president of the Arizona Obesity Organization. Slug: ...
MedPage Today4hOpinion
The Rise in Adolescent Bariatric Surgery Doesn't Mean GLP-1s Have Failed
When glucagon-like peptide-1 receptor agonists (GLP-1s) like semaglutide (Wegovy) and liraglutide (Saxenda) were approved for ...